QIAGEN Share Holder Equity 2010-2022 | QGEN

QIAGEN share holder equity from 2010 to 2022. Share holder equity can be defined as the sum of preferred and common equity items
  • QIAGEN share holder equity for the quarter ending June 30, 2022 was $3.282B, a 10.23% increase year-over-year.
  • QIAGEN share holder equity for 2021 was $3.097B, a 10.68% increase from 2020.
  • QIAGEN share holder equity for 2020 was $2.798B, a 10.3% increase from 2019.
  • QIAGEN share holder equity for 2019 was $2.537B, a 3.73% decline from 2018.
QIAGEN Annual Share Holder Equity
(Millions of US $)
2021 $3,097
2020 $2,798
2019 $2,537
2018 $2,635
2017 $2,541
2016 $2,607
2015 $2,568
2014 $2,658
2013 $2,724
2012 $2,724
2011 $2,558
2010 $2,476
2009 $2,291
QIAGEN Quarterly Share Holder Equity
(Millions of US $)
2022-06-30 $3,282
2022-03-31 $3,240
2021-12-31 $3,097
2021-09-30 $3,014
2021-06-30 $2,978
2021-03-31 $2,850
2020-12-31 $2,798
2020-09-30 $2,711
2020-06-30 $2,621
2020-03-31 $2,492
2019-12-31 $2,537
2019-09-30 $2,467
2019-06-30 $2,632
2019-03-31 $2,606
2018-12-31 $2,635
2018-09-30 $2,527
2018-06-30 $2,524
2018-03-31 $2,581
2017-12-31 $2,541
2017-09-30 $2,567
2017-06-30 $2,505
2017-03-31 $2,430
2016-12-31 $2,607
2016-09-30 $2,666
2016-06-30 $2,627
2016-03-31 $2,625
2015-12-31 $2,568
2015-09-30 $2,520
2015-06-30 $2,537
2015-03-31 $2,479
2014-12-31 $2,658
2014-09-30 $2,714
2014-06-30 $2,755
2014-03-31 $2,733
2013-12-31 $2,724
2013-09-30 $2,676
2013-06-30 $2,595
2013-03-31 $2,691
2012-12-31 $2,724
2012-09-30 $2,712
2012-06-30 $2,642
2012-03-31 $2,635
2011-12-31 $2,558
2011-09-30 $2,585
2011-06-30 $2,594
2011-03-31 $2,536
2010-12-31 $2,476
2010-09-30 $2,430
2010-06-30 $2,335
2010-03-31 $2,311
2009-12-31 $2,291
2009-09-30 $2,228
2009-06-30 $1,535
2009-03-31 $1,462
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $9.383B $2.252B
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $150.984B 9.16
GSK (GSK) United Kingdom $59.709B 7.17
Bio-Rad Laboratories (BIO.B) United States $12.433B 27.47
Biohaven Pharmaceutical Holding (BHVN) United States $10.873B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.998B 0.00
Arcus Biosciences (RCUS) United States $1.819B 35.51
Myovant Sciences (MYOV) United Kingdom $1.614B 0.00
Emergent Biosolutions (EBS) United States $1.040B 6.03
ADC Therapeutics SA (ADCT) Switzerland $0.376B 0.00
Zymeworks (ZYME) Canada $0.305B 0.00
Enzo Biochem (ENZ) United States $0.105B 0.00
Gelesis Holdings (GLS) United States $0.081B 0.00
SQZ Biotechnologies (SQZ) United States $0.068B 0.00
Ambrx Biopharma (AMAM) United States $0.041B 0.00